One industry already ran the experiment of winning public trust by curing a disease. In 2013 Gilead released a pill that cured hepatitis C. Over 95% cure rate, twelve weeks, one pill a day. The reward was a Senate investigation and the worst trust numbers in American industry. Gilead priced Sovaldi at $84,000 per course, $1,000 per pill, for a drug that cost roughly $100 to manufacture. Insurers rationed it to the sickest patients. State Medicaid programs got sued for restricting access. The…